Elizabeth Ruth Plummer

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

Yvette Drew, Evan A. Mulligan, Wan-Tse Vong et al. · JNCI Journal of the National Cancer Institute · 2010 · 261 citations · Full text

Medicine, Oncology, Pharmacology +14

Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Asima Mukhopadhyay, Elizabeth Ruth Plummer, Ahmed Elattar et al. · Cancer Research · 2012 · 165 citations · Full text

Medicine, Oncology, Pharmacology +17

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <i>O</i>6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Elizabeth Ruth Plummer, Mark R. Middleton, Christopher J. Jones et al. · Clinical Cancer Research · 2005 · 103 citations

Medicine, Oncology, Cancer Pharmacology +16

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Rachel Daniel, Agata Rozanska, Huw D. Thomas et al. · Clinical Cancer Research · 2009 · 82 citations

Medicine, Oncology, Pharmacology +15

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

Tomasz Zaremba, Patrick Ketzer, Michael Cole et al. · British Journal of Cancer · 2009 · 72 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +16